{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:56:19Z","timestamp":1791888979718,"version":"4.3.4"},"reference-count":66,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia, a specific clonal B-cell disorder of the bone marrow, and a monoclonal gammopathy of clinical significance. Thus, CAD should be distinguished from cold agglutinin syndrome, a more heterogeneous cold hemolytic syndrome that occurs secondary to other clinical disease. Cold agglutinins in CAD are usually of the immunoglobulin M kappa class with a heavy chain variable region encoded by the IGHV4-34 gene segment. The hemolytic anemia is entirely mediated by classical complement activation, which also explains some additional clinical features, such as fatigue and acute exacerbations. Non-complement-mediated steps in pathogenesis are also essential, such as erythrocyte agglutination and, probably, coexistent cryoglobulin activity in some patients, resulting in cold-induced circulatory symptoms. Based on this heterogeneity, different clinical phenotypes can be defined and used to guide individualized treatment. Established therapies aim at targeting the pathogenic B-cell clone or the classical complement activation pathway. Novel and investigational therapies include Bruton's tyrosine kinase inhibitors, plasma cell\u2013directed therapies, novel complement inhibitors, and entirely new approaches such as cytokine inhibitors and, possibly, antibodies specific for the VH4-34 protein sequence. Patients with CAD requiring therapy should be considered for clinical trials.<\/jats:p>","DOI":"10.1182\/hematology.2025000718","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:25Z","timestamp":1764943705000},"page":"295-304","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Diagnosis and management of cold agglutinin disease"],"prefix":"10.1182","volume":"2025","author":[{"given":"Sigbj\u00f8rn","family":"Berentsen","sequence":"first","affiliation":[{"name":"Department of Research and Innovation, Haugesund Hospital, Helse Fonna HF, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025120616331629700_hem2025000718C1","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"3","key":"2025120616331629700_hem2025000718C2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ajh.2830020308","article-title":"Hemolysis by complement and cold- reacting antibodies: time and temperature requirements","volume":"2","author":"Rosse","year":"1977","journal-title":"Am J Hematol"},{"issue":"10","key":"2025120616331629700_hem2025000718C3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"issue":"6281","key":"2025120616331629700_hem2025000718C4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/bmj.282.6281.2023","article-title":"Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre","volume":"282","author":"Sokol","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"19","key":"2025120616331629700_hem2025000718C5","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2025120616331629700_hem2025000718C6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"key":"2025120616331629700_hem2025000718C7","first-page":"599","article-title":"Cold agglutinin disease","volume-title":"WHO Classification of Tumours: Haematolymphoid Tumours","author":"Naresh","year":"2024","edition":"5"},{"issue":"4","key":"2025120616331629700_hem2025000718C8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2025120616331629700_hem2025000718C9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ajcp\/aqad048","article-title":"The histopathology of cold agglutinin disease-associated B-cell lymphoproliferative disease","volume":"160","author":"Guenther","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2025120616331629700_hem2025000718C10","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2025120616331629700_hem2025000718C11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17474086.2024.2372333","article-title":"The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms","volume":"17","author":"Berentsen","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2025120616331629700_hem2025000718C12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.hoc.2015.01.002","article-title":"Cold agglutinin-mediated autoimmune hemolytic anemia","volume":"29","author":"Berentsen","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2025120616331629700_hem2025000718C13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2025120616331629700_hem2025000718C14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"2025120616331629700_hem2025000718C15","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2016.146126","article-title":"Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity","volume":"101","author":"Ma\u0142ecka","year":"2016","journal-title":"Haematologica"},{"key":"2025120616331629700_hem2025000718C16","doi-asserted-by":"crossref","first-page":"1259827","DOI":"10.3389\/fimmu.2023.1259827","article-title":"Human VH4-34 antibodies derived from B1 cells are more frequently autoreactive than VH4-34 antibodies derived from memory cells","volume":"14","author":"Ray","year":"2023","journal-title":"Front Immunol"},{"issue":"26","key":"2025120616331629700_hem2025000718C17","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025120616331629700_hem2025000718C18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/cei\/uxad135","article-title":"Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease","volume":"216","author":"Ma\u0142ecka","year":"2024","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2025120616331629700_hem2025000718C19","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2025120616331629700_hem2025000718C20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/bjh.19185","article-title":"Cold agglutinin disease and cryoglobulinaemia: a frequent coexistence with clinical impact","volume":"204","author":"Khwaja","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"2025120616331629700_hem2025000718C21","doi-asserted-by":"crossref","first-page":"e0276617","DOI":"10.1371\/journal.pone.0276617","article-title":"Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: analysis of an integrated claim-clinical cohort in the United States","volume":"17","author":"Broome","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"2025120616331629700_hem2025000718C22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1-2","key":"2025120616331629700_hem2025000718C23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-3083.2001.00960.x","article-title":"Acute phase haemolysis in chronic cold agglutinin disease","volume":"54","author":"Ulvestad","year":"2001","journal-title":"Scand J Immunol"},{"key":"2025120616331629700_hem2025000718C24","doi-asserted-by":"crossref","first-page":"1180509","DOI":"10.3389\/fimmu.2023.1180509","article-title":"The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?","volume":"14","author":"Berentsen","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"2025120616331629700_hem2025000718C25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/trf.16279","article-title":"In from the cold: M-protein light chain glycosylation is positively associated with cold agglutinin titer levels","volume":"61","author":"Juskewitch","year":"2021","journal-title":"Transfusion"},{"issue":"11-12","key":"2025120616331629700_hem2025000718C26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00508-014-0547-z","article-title":"Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings","volume":"126","author":"Arthold","year":"2014","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"2025120616331629700_hem2025000718C27","doi-asserted-by":"crossref","first-page":"E279","DOI":"10.1002\/ajh.26205","article-title":"The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels","volume":"96","author":"Ma\u0142ecka","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"2025120616331629700_hem2025000718C28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2020001608","article-title":"Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18","volume":"4","author":"Ma\u0142ecka","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2025120616331629700_hem2025000718C29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease","volume":"183","author":"Ma\u0142ecka","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120616331629700_hem2025000718C30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/trf.16745","article-title":"Complement-mediated hemolysis persists year round in patients with cold agglutinin disease","volume":"62","author":"R\u00f6th","year":"2022","journal-title":"Transfusion"},{"issue":"7","key":"2025120616331629700_hem2025000718C31","doi-asserted-by":"crossref","first-page":"E262","DOI":"10.1002\/ajh.26196","article-title":"Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy","volume":"96","author":"Hansen","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"2025120616331629700_hem2025000718C32","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/trf.16894","article-title":"Mortality in cold agglutinin disease shows seasonal pattern","volume":"62","author":"Hansen","year":"2022","journal-title":"Transfusion"},{"issue":"12","key":"2025120616331629700_hem2025000718C33","first-page":"1419","article-title":"An observational analysis of disease burden in patients with cold agglutinin disease: results from a large US electronic health record database","volume":"28","author":"Pham","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"2025120616331629700_hem2025000718C34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124034","article-title":"Rituximab use in warm and cold autoimmune hemolytic anemia","volume":"9","author":"Murakhovskaya","year":"2020","journal-title":"J Clin Med"},{"issue":"5","key":"2025120616331629700_hem2025000718C35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14712598.2023.2209265","article-title":"Monoclonal antibodies for treatment of cold agglutinin disease","volume":"23","author":"Gelbenegger","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2025120616331629700_hem2025000718C36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/17474086.2024.2366540","article-title":"The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease","volume":"17","author":"Barcellini","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2025120616331629700_hem2025000718C37","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2025120616331629700_hem2025000718C38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025120616331629700_hem2025000718C39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025120616331629700_hem2025000718C40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025120616331629700_hem2025000718C41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2025120616331629700_hem2025000718C42","doi-asserted-by":"crossref","first-page":"e28679","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"2025120616331629700_hem2025000718C43","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"2025120616331629700_hem2025000718C44","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"issue":"9","key":"2025120616331629700_hem2025000718C45","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"2025120616331629700_hem2025000718C46","doi-asserted-by":"crossref","first-page":"102733","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2025120616331629700_hem2025000718C47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12185-024-03842-9","article-title":"Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease","volume":"120","author":"Miyakawa","year":"2024","journal-title":"Int J Hematol"},{"issue":"1","key":"2025120616331629700_hem2025000718C48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14740\/jh242w","article-title":"A novel approach for treatment of cold agglutinin syndrome-related severe hemolysis","volume":"5","author":"Tesfaye","year":"2016","journal-title":"J Hematol"},{"issue":"19","key":"2025120616331629700_hem2025000718C49","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"33","key":"2025120616331629700_hem2025000718C50","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025120616331629700_hem2025000718C51","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025120616331629700_hem2025000718C52","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.25932","article-title":"Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy","volume":"95","author":"Tomkins","year":"2020","journal-title":"Am J Hematol"},{"key":"2025120616331629700_hem2025000718C53","doi-asserted-by":"crossref","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"2025120616331629700_hem2025000718C54","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2025120616331629700_hem2025000718C55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2023022153","article-title":"Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study","volume":"143","author":"D'Sa","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025120616331629700_hem2025000718C56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/ph18020210","article-title":"Current trends in clinical trials of prodrugs","volume":"18","author":"Boreski","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"2025120616331629700_hem2025000718C57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616331629700_hem2025000718C58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.HS9.0000561876.96057.48","article-title":"Inhibition of C3 with APL-2 controls haemolysis and increases haemoglobin levels in subjects with autoimmune haemolytic anaemia (AIHA)","volume":"3","author":"Gertz","year":"2019","journal-title":"HemaSphere"},{"issue":"16","key":"2025120616331629700_hem2025000718C59","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"key":"2025120616331629700_hem2025000718C60","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-219066","article-title":"Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease","volume-title":"BMJ Case Rep","author":"Tj\u00f8nnfjord","year":"2017"},{"key":"2025120616331629700_hem2025000718C61","doi-asserted-by":"crossref","first-page":"1228142","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia: epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"2025120616331629700_hem2025000718C62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2025120616331629700_hem2025000718C63","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1182\/blood-2023-179305","article-title":"Initial report of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoimmune cytopenias: the RUBY-4 study","volume":"142","author":"Broome","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025120616331629700_hem2025000718C64","first-page":"238.220","article-title":"Selective targeting of pathogenic auto-reactive VH4-34 B cells with a rationally developed anti-VH4-34 antibody offers a new therapeutic approach for autoimmune disorders. Presented at the Immunology 2023 Congress","volume":"210","author":"Paliwal","year":"2023","journal-title":"J Immunol"},{"issue":"1","key":"2025120616331629700_hem2025000718C65","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/hemato3040040","article-title":"Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy","volume":"3","author":"Berentsen","year":"2022","journal-title":"Hemato"},{"issue":"2","key":"2025120616331629700_hem2025000718C66","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1002\/ajh.26409","article-title":"Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery","volume":"97","author":"Tvedt","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/295\/2470519\/295berentsen.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/295\/2470519\/295berentsen.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:28Z","timestamp":1765056808000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/295\/556922\/Diagnosis-and-management-of-cold-agglutinin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000718","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}